Online inquiry

IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14579MR)

This product GTTS-WQ14579MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14579MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7422MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ5074MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ2582MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ9884MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ1293MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ9025MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ2075MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ13455MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW